Comparison of Safety Profiles of the New and Old Formulations of Levothyroxine in a First Global Introduction in France
| Autor: | Jean-Louis Wémeau, Hendrik Lehnert, Bushan Channaiah, Karine Martiniere, Claire Castello-Bridoux, Steven Hildemann |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Drug Compounding Endocrinology Diabetes and Metabolism Levothyroxine 030209 endocrinology & metabolism MARKETING AUTHORIZATION HOLDER Bioequivalence 03 medical and health sciences 0302 clinical medicine Endocrinology Internal Medicine medicine Humans 030212 general & internal medicine Adverse effect Retrospective Studies business.industry General Medicine Thyroxine Safety profile Patient population Therapeutic Equivalency France business medicine.drug Levothyroxine Sodium |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 129:908-917 |
| ISSN: | 1439-3646 0947-7349 |
| DOI: | 10.1055/a-1302-9343 |
| Popis: | Background Levothyroxine sodium marketed in France was reformulated following a French National Agency for Medicines and Health Products Safety request for a more stringent potency specification. Despite previously established purity and bioequivalence of the new and old formulations, reports of adverse events substantially increased following reformulation. This analysis evaluated the nature and relevance of the medically confirmed safety reports. Methods Spontaneous and solicited individual case safety reports in France were retrieved from 26 March 2015 to 30 June 2016 (old formulation) and 26 March 2017 to 30 June 2018 (new formulation). Rates of reports and adverse events were calculated for the overall patient population and for at-risk subgroups. Adverse events delineated by thyroid-stimulating hormone levels were evaluated. Results A total of 295 and 42 775 reports for the old formulation and new formulation, respectively, were retrieved, with 149 and 5503 medically confirmed. The most common medically confirmed adverse events were consistent with the known safety profile of levothyroxine, with generally comparable rates between both formulations (range of differences, 1.8–4.1%). Most cases were not serious (old formulation, 65.8%; new formulation, 78.7%). Reporting rates were similar or higher for the old formulation within subgroups of at-risk patients. Nature/distributions of adverse events by thyroid-stimulating hormone levels as determined by both the marketing authorization holder of levothyroxine and the French National Agency for Medicines and Health Products Safety were similar. Conclusions The new formulation safety profile aligns with the established profile of the old formulation of levothyroxine. The benefit–risk profile is unchanged, such that the benefits of using the new formulation in the approved indications outweigh the risks associated with the treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|